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 24 
ABSTRACT 25 
The attenuated rabies virus (RV) strain Challenge Virus Standard (CVS)-F3 and a 26 
highly pathogenic strain associated with the silver-haired bats (SHBRV) can both be cleared 27 
from the central nervous system (CNS) tissues by appropriate anti-viral immune mechanisms 28 
if the effectors are provided access across the blood-brain barrier (BBB). In the case of 29 
SHBRV infection anti-viral immunity develops normally in the periphery but fails to open the 30 
BBB, generally resulting in a lethal outcome. To determine whether or not an absence in the 31 
CNS targeted immune response is associated with the infection with other pathogenic RV 32 
strains we have assessed the development of immunity, BBB permeability and immune cell 33 
infiltration into the CNS tissues of mice infected with a variety of RV strains including the 34 
dog variants responsible for the majority of human rabies cases. We demonstrate that the 35 
lethal outcomes of infection with a variety of known pathogenic RV strains are indeed 36 
associated with the inability to deliver immune effectors across the BBB. Survival from 37 
infection with certain of these viruses is improved in mice prone to CNS inflammation. The 38 
results suggest that competition between the activity of the immune effectors reaching CNS 39 
tissues and the inherent pathological attributes of the virus dictates the outcome and that 40 
intervention to deliver RV-specific immune effectors into CNS tissues may have general 41 
therapeutic value in rabies.  42 
 43 
 44 
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INTRODUCTION 45 
Rabies has been known for centuries as a deadly neurological disease of both humans 46 
and animals. The causative agent belongs to a group of antigenically related viruses named 47 
after the disease, the rabies viruses (RV). RV strains varying in their genotypes and 48 
pathogenicity can be found associated with diverse reservoir species in different geographic 49 
locations (Kissi et al., 1995). Each RV strain is associated with a particular natural host 50 
species, usually canines and other small carnivores, such as raccoons and skunks as well as 51 
bats (Baer et al., 1990). RV strains associated with dogs are the major cause of human rabies 52 
worldwide due to prevalence of the virus in developing countries, while an RV strain 53 
associated with silver-haired bat (SHBRV) is responsible for most of the endogenous human 54 
rabies cases in the United States and Canada (Messenger et al., 2003).   55 
While rabies is generally fatal once the early clinical signs of the disease appear, 56 
prompt treatment measures that include wound cleansing and passive administration of RV-57 
neutralizing antibodies together with active immunization can prevent development of the 58 
disease in an individual exposed to the virus (Fu, 1997). This approach, called post-exposure 59 
prophylaxis (PEP), fails to protect an infected individual once neurological signs are apparent 60 
(CDC MMWR, 1999). Since neurological signs are indicative of virus replication in the 61 
central nervous system (CNS) tissues, it is generally considered to be impossible to clear the 62 
virus and save a RV infected individual once RV has spread to the brain from its peripheral 63 
site of entry. However, this is not always the case. In a well-documented recent example, a 64 
rabies patient who developed evidence of antiviral immunity recovered despite developing 65 
severe neurological signs (Willoughby et al., 2005). There is also historical evidence of 66 
individuals surviving likely infections with the virus (Gremliza, 1953; Hattwick et al, 1972) as 67 
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well as laboratory evidence that RV can be cleared from the CNS tissues if appropriate 68 
immune mechanisms develop (Jackson et al., 1989). We have recently elucidated several of 69 
the processes required to clear the attenuated RV strain Challenge Virus Standard (CVS)-F3 70 
from the CNS (Phares et al., 2006). These include the development of an innate immune 71 
response in the CNS tissues and adaptive RV-specific immunity in the peripheral lymphoid 72 
organs as well as the infiltration of immune effectors across the blood-brain barrier (BBB) 73 
(Phares et al., 2006). The latter is associated with increased BBB permeability to fluid phase 74 
markers primarily in the cerebellum of the infected mice (Phares et al., 2006). We have 75 
determined that the BBB remains intact and immune cells do not enter the CNS tissues in 76 
animals infected with SHBRV (Roy et al., 2007). Consequently, the virus is not cleared and 77 
SHBRV-infected animals die of rabies (Roy et al., 2007). Increasing BBB permeability in 78 
SHBRV infected animals through the induction of an autoimmune CNS inflammatory 79 
response facilitates immune cell entry into the infected CNS tissues and promotes virus 80 
clearance thereby preventing the lethal outcome of the infection (Roy and Hooper, 2007). 81 
White blood cells and virus specific antibodies was also found to accumulate in the CSF in a 82 
patient who survived clinical rabies (Willoughby et al., 2005). 83 
Unlike classical rabies, which results from the bite of an infected dog an incident 84 
causing infection with SHBRV often goes unnoticed (Jackson and Fenton, 2001; CDC 85 
MMWR, 1999, 2007), leading to speculation that these variants may have unique attributes, 86 
possibly including the capacity to evade immune clearance. Alternatively, all pathogenic RV 87 
strains may interfere with antiviral immune mechanisms at some stage of the infection, an 88 
attribute that would explain the failure of PEP later in the disease. To distinguish between 89 
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these alternatives we have assessed BBB function and immune cell invasion into the CNS 90 
tissues of mice infected with a variety of RV strains. 91 
 6 
MATERIALS AND METHODS 92 
Animals and virus.  93 
129/SvEv mice were obtained from the in-house breeding colony at Thomas Jefferson 94 
University and PLSJLF1/J (PLSJL) mice were purchased from Jackson Laboratories (Bar 95 
harbor, ME). Eight to 10 -week old mice (n ≥ 10 per group) were infected via intra-dermal 96 
(ID) route in the ear as previously described (Roy et al., 2007). The inoculation dose used and 97 
a brief description of each RV strain studied are presented in Table 1. The doses for the 98 
pathogenic RV strains were approximately 10×LD50 (ID) in mouse. Cell culture adapted 99 
strains that are not lethal for immunocompetent animals were administered at 105 focus 100 
forming units, an amount that is known to cause CNS infection for CVS-F3 (Phares et al., 101 
2006). All procedures were carried out according to the protocols approved by the 102 
Institutional Animal Care and Use Committee of Thomas Jefferson University.  103 
 104 
Tissue collection.  105 
Mice were anesthetized and the thoracic cavity was surgically opened. Cardiac blood 106 
was collected and mice were transcardially perfused with 15 mL of PBS supplemented with 107 
1U/mL Heparin followed by 15 mL of PBS. Brains were collected and the cerebral cortex and 108 
the cerebellum were separated. Tissues were snap frozen in liquid nitrogen and stored at –109 
80oC until further use. 110 
 111 
RT-PCR.  112 
As an indicator of virus replication, RV nucleoprotein-specific mRNA levels were 113 
measured in the CNS tissues from infected mice by the reverse transcriptase–polymerase 114 
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chain reaction (RT-PCR) technique. Briefly, total RNA was isolated from the snap frozen 115 
brain tissues of RV-infected and uninfected control mice using the Qiagen RNeasy Kit 116 
(Valencia, CA) as previously described (Phares et al., 2006). cDNAs were synthesized from 117 
mRNA by reverse transcription using oligo (dT) as primer. Approiximately 100 ng of cDNA 118 
was subjected to PCR amplification using primers specific for a segment of nucleoprotein 119 
gene that is largely conserved among all of the virus strains used in the current study. The 120 
gene for the house-keeping ribosomal protein L-13 was quantified in each sample to ensure 121 
that the quantities of cDNA used for PCR are almost equal in all samples. The nucleotide 122 
sequences of the primers used for PCR are: forward primer for RV nucleoprotein gene, 5’-TA 123 
CAATGGATGCCGACAAGA -3’; reverse primer for RV nucleoprotein gene, 5’-AAAGGG 124 
GCTGTCTCGAAAAT-3’; forward primer for L-13, 5’-TTCCACAAGGATTGGCAGCA-3’; 125 
and reverse primer for L-13, 5’-TGCTCGGATTGCCAAAGAGT-3’. Equal amounts of the 126 
PCR products were subjected to gel electrophoresis using 1% agarose gel and bands of 127 
amplified DNA were visualized under UV light and photographed using a gel-documentation 128 
system (Bio-Rad). 129 
 130 
Quantitative Real Time-PCR  131 
The levels of mRNAs specific for TNF-α, IL-6, CD4, CD19 and κ-light chain genes 132 
were measured in cDNA samples by quantitative real-time PCR (QRT-PCR) as previously 133 
described, using TaqMan PCR reagents (Applied Biosystems, Foster City, CA), gene-specific 134 
primers and probes, synthetic gene standards, and a Bio-Rad iCycler iQ Real Time Detection 135 
System (Hercules, CA) (Phares et al., 2006). In each sample, the mRNA copy numbers of a 136 
particular gene were normalized to the mRNA copy number of the housekeeping gene L13. 137 
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Levels of gene expression in a test sample are presented as the fold increase over that detected 138 
in uninfected controls using the formula: n-fold increase = [mRNA copy numbers of a 139 
particular gene in a RV-infected sample/ mRNA copy numbers of L13 in that sample] / 140 
average of [mRNA copy numbers of that particular gene in an uninfected mouse sample / 141 
mRNA copy numbers of L13 in that sample]. The sequences of the primers and probes used 142 
for quantitative PCR have been previously detailed (Phares et al., 2006). 143 
 144 
Measurement of serum antibody titers.   145 
Levels of RV-specific total immunoglobulin-gamma (IgG) in sera from uninfected and 146 
RV-infected mice were measured by Enzyme Linked Immunosorbent Assay (ELISA) as 147 
described previously (Roy et al., 2007). Briefly, serially diluted sera samples were incubated 148 
at room temperature in 96-well plates (Nalge Nunc International, Rochester, NY) coated with 149 
UV-inactivated Evelyn-Rokitnicki-Abelseth (ERA) or CVS-F3 (5µg/ml). Captured antibodies 150 
were detected using peroxidase-conjugated anti-mouse IgG (Sigma). 3, 3’, 5, 5’ – 151 
Tetramethylbenzidine dihydrochloride substrate (Sigma) supplemented with hydrogen 152 
peroxide was used for color development. The reaction was terminated by the addition of 2M-153 
H2SO4 to the wells and the absorbance was measured at 450 nm in a microplate 154 
spectrophotometer (Biotek, Winooski, VT). Antibody titer is calculated as the inverse of the 155 
dilution of a serum sample corresponding to the half of the maximum absorbance detected in 156 
that sample. 157 
 158 
Assessment of BBB permeability.  159 
The extent of BBB permeability was assessed by measuring the amount of a low 160 
molecular weight fluorescent marker (Na-fluorescein, molecular weight 376) that leaks from 161 
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the circulation into the CNS tissues as previously described (Phares et al., 2006). Briefly, 162 
100µl of 10% solution of Na-fluorescein was injected intra-peritoneally and after 10 minutes 163 
mice were anesthetized and transcardially perfused as described above. Snap frozen brains 164 
were homogenized in phosphate buffered saline (PBS) and centrifuged. Proteins from the 165 
supernatants of the tissue homogenate as well as from serum samples were precipitated with 166 
15% TCA. Fluorescence in the clarified supernatant was measured at excitation and emission 167 
wavelengths of 485nm and 530nm respectively, using a CytoFluorII fluorimeter (PerSeptive 168 
Biosystems, Framingham, MA). The amount of Na-fluorescein in the CNS tissue of each 169 
animal was normalized to the level of Na-fluorescein detected in the animal’s serum using the 170 
formula: Na-fluorescein uptake = [amount of Na-fluorescein detected in the CNS tissue of a 171 
mouse/ weight of the tissue]/ amount of Na-fluorescein detected per µL of serum of that 172 
mouse. Na-fluorescein uptake into the tissues of each infected animal was divided by the 173 
average uptake detected in similar tissues from uninfected control mice and the results are 174 
expressed as fold increase.   175 
 176 
Statistical analyses.  177 
Results are expressed as the mean ± the standard error of the mean. The statistical 178 
significance of the differences in gene expression and in serum antibody levels between 179 
control and infected groups was assessed using the Mann-Whitney test while the t-test was 180 
used to test the significance of differences in virus nucleoprotein mRNA levels.  181 
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RESULTS 182 
 183 
The outcomes of infection with different RV strains differ.  184 
Ten different RV strains ERA, PM, CVS-F3, DRV-4, Thai-DRV, CVS-N2c, CosRV, 185 
SkunkRV, SHBRV and HEP were used in the current study (see Table 1). Groups of 186 
129/SvEv mice were infected via the ID route with each of the RV strains and 8 days 187 
following infection, RT-PCR was used to detect the presence of viral nucleoprotein mRNA in 188 
the CNS tissues. Viral nucleoprotein message was found in the cortices and the cerebella of 189 
all infected mice, with the exception of those that had received the HEP strain (Fig 1). We 190 
were unable to detect nucleoprotein message for HEP by RT-PCR in any part of the CNS 191 
tissues (olfactory bulbs, cerebral cortex, cerebellum, brain stem and spinal cord) following 192 
either ID or intra-nasal administration of HEP (data not shown). However, HEP nucleoprotein 193 
mRNA can be detected in cell culture by RT-PCR using the same set of RV specific primers 194 
used in this study.  195 
Similar groups of infected 129/SvEv mice were monitored for mortality. Mice infected 196 
with Thai-DRV, CVS-N2c and SHBRV died around 8-12 days postinfection whereas mice 197 
infected with DRV-4, CosRV and SkunkRV died within 12-17 days after infection (Fig 2). 198 
Despite the fact that the relatively less pathogenic RV strains, namely ERA, PM and CVS-F3, 199 
reached the CNS, mice infected with these strains of RV survived the infection (Fig 2). Mice 200 
receiving the HEP RV strain survived without any sign of disease over a 30-day observation 201 
period.  202 
 203 
 204 
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Innate immunity is induced in the CNS by all neuroinvasive RV strains.  205 
When RV reaches the CNS tissues it induces the expression of pro-inflammatory 206 
cytokines of the innate immune response (Phares et al., 2006; Marquette et al., 1996). A 207 
difference in the capacity of different RV strains to induce a CNS innate immunity has been 208 
suggested to be associated with the pathogenicity of that virus (Wang et al., 2005). Infection 209 
with all of the RV strains that reached the CNS of the 129/SvEv mice upregulates the 210 
expression of genes specific for the pro-inflammatory cytokines TNF-α and IL-6 (Fig 3). 211 
Moreover, the expression of these genes is elevated to more or less equivalent extents 212 
irrespective of the pathogenicity of the RV strain. Enhanced TNF-α and IL-6 expression was 213 
not seen in the CNS of mice receiving HEP RV, providing support for the likelihood that this 214 
particular RV strain is not neuroinvasive. 215 
 216 
 217 
All RV infections induce strong RV-antigen specific antibody response. 218 
As shown in Fig 4, regardless of the pathogenicity of the infecting virus, all RV 219 
infected animals including those receiving HEP, developed an RV-specific IgG response. The 220 
serum antibody titers raised by infection with the different viruses were approximately the 221 
same with the exception of mice infected with the ERA strain where substantially higher 222 
serum antibody titers were seen. Notably, although no evidence of either virus replication or 223 
induction of pro-inflammatory genes in the CNS of HEP infected mice was detected, serum 224 
RV-specific antibody titers in these mice were equivalent to those of mice infected with other 225 
RV strains.  226 
 227 
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Virus is cleared and animals survive only where anti-RV adaptive immune effectors reach 228 
the CNS. 229 
Clearance of RV from the CNS requires the invasion of the CNS tissues by immune 230 
cells, a process that primarily occurs in the cerebellum and, for CVS-F3, involves the activity 231 
of CD4 T-cells and B cells (Phares et al., 2006 and 2007). In the absence of the accumulation 232 
of these immune effectors in CNS tissues, RV infection is lethal (Roy et al., 2007). Eight days 233 
following infection, the expression of the mRNAs specific for CD4, CD19 (phenotypic 234 
markers for T- and B-cells, respectively) and κ-light chain (an indicator of antibody 235 
production by B-cells) is greatly elevated in the cerebella of mice infected with the less 236 
pathogenic ERA, PM and CVS-F3 strains of RV (Fig 5). On the other hand, no significant 237 
increase in the expression levels of these genes is seen in the cerebella of mice infected with 238 
the pathogenic RV strains DRV-4, Thai-DRV, CVS-N2c, CosRV, SHBRV and SkunkRV 239 
(Fig 5).  240 
As immune-cell infiltration into the CNS tissues of CVS-F3 infected mice is 241 
accompanied by an increase in BBB permeability to the fluid phase marker Na-fluorescein, 242 
we next assessed BBB integrity during infection with the different RV strains. The results 243 
paralleled the difference in immune cell invasion of CNS tissues between less pathogenic and 244 
pathogenic strains of RV. BBB permeability in the cerebellum was indeed significantly 245 
enhanced in animals infected with ERA, PM and CVS-F3 strains, but not in animals infected 246 
with DRV-4, Thai-DRV, CVS-N2c, CosRV, SHBRV and SkunkRV strains (Fig 6). 247 
 248 
 249 
 250 
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PLSJL mice are more resistant to the death from infection with different pathogenic RV 251 
strains. 252 
We have previously shown that PLSJL mice are somewhat more resistant to lethal 253 
infection with SHBRV than 129/SvEv mice (Roy and Hooper, 2007). To test if PLSJL mice 254 
are less susceptible to lethal infection with other pathogenic RV strains, groups of 129/SvEv 255 
and PLSJL mice were infected with different RV strains and monitored for clinical signs of 256 
rabies and mortality for a period of 30 days post infection. Between 8 to 15 days after 257 
infection, 129/SvEv mice infected with all RV strains, except HEP, showed prominent 258 
neurological signs of rabies (Table 2). Those infected with the pathogenic DRV-4, Thai-DRV, 259 
CVS-N2c, CosRV, SHBRV and SkunkRV strains died within 2-5 days of the appearance of 260 
clinical signs, whereas 129/SvEv mice infected with the less pathogenic ERA, PM and CVS-261 
F3 strains survived. ERA infected 129/SvEv mice had persistent neurological signs for over 262 
10-15 days after first appearance, but nevertheless survived the infection. On the other hand, 263 
almost all of the PLSJL mice infected with ERA, PM and CVS-F3 as well as DRV-4, CosRV 264 
and SkunkRV survived the infection without any sign of disease (Table 2). Only one mouse in 265 
each of the CosRV and Skunk RV infected groups developed neurological signs and both died 266 
of rabies. However, the majority of Thai-DRV, CVS-N2c and SHBRV infected PLSJL mice 267 
died of rabies after developing neurological signs similar to those appearing in 129/SvEv mice 268 
infected with the same RV strains. The PLSJL mice that survived infection with these viruses 269 
did not develop any signs of clinical rabies (Table 2). As an initial probe into why PLSJL 270 
mice may survive infections with RV strains that are lethal for 129/SvEv mice we used 271 
quantitative RT-PCR to assess the amounts of virus nucleoprotein message in the CNS of 272 
mice infected with two RV strains, CosRV, which is pathogenic in 129/SvEv mice but non-273 
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pathogenic in PLSJL mice, and CVS-N2c, which is pathogenic in both 129/SvEv and PLSJL 274 
mice. At 8 days of infection, the levels of nucleoprotein mRNA of the more pathogenic CVS-275 
N2c strain were several thousands fold higher in the CNS of both 129/SvEv and PLSJL mice 276 
than those of the CosRV strain (Fig 7). However, the nucleoprotein mRNA levels of both 277 
viruses were significantly lower in PLSJL mice (Fig 7). Significantly, the only group of mice 278 
that survive, PLSJL mice infected with CosRV, exhibits the lowest viral nucleoprotein mRNA 279 
levels.  280 
 281 
 282 
 283 
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DISCUSSION 284 
We have previously shown that while RV-specific immunity develops in the periphery 285 
of mice infected with either the attenuated variant CVS-F3 or the highly pathogenic SHBRV, 286 
immune effectors are not delivered across the BBB into the CNS tissues of the latter (Roy et 287 
al., 2007). These findings led us to speculate that the mechanisms providing RV-specific 288 
immune effectors access to CNS tissues fail during infection with SHBRV and possibly other 289 
neurotropic viruses (Roy et al., 2007). In this study we have tested the hypothesis with respect 290 
to pathogenic RV by comparing the development of peripheral and CNS immunity in mice 291 
infected with a variety of RV strains that differ in pathogenicity. The data clearly show that a 292 
reduction in the capacity to deliver immune effectors across the BBB into CNS tissues is 293 
common to infection with different pathogenic RV isolates. In our survey of infection with 294 
diverse RV variants we identified only a single strain, HEP, that does not appear to spread to 295 
the CNS of 129/SvEv mice. We failed to detect viral message or evidence of innate immunity 296 
to the virus in CNS tissues from mice infected with HEP, which is considered to be poorly 297 
neuroinvasive due to the presence of glutamine at position 333 in its glycoprotein 298 
(Dietzschold et al, 1983; Takayama-Ito et al., 2006). Nevertheless, the administration of HEP 299 
stimulated a strong RV-specific antibody response. In contrast, all of the other RV strains 300 
tested were neuroinvasive as nucleoprotein mRNAs were detectable in the CNS tissues, as 301 
were elevations in markers of innate immunity. DRV-4, Thai-DRV, CVS-N2c, CosRV and 302 
Skunk RV were lethal for 129/SvEv mice, while similar mice infected with CVS-F3, ERA 303 
and PM strains survived. Unlike CVS-F3-infected mice where neurological disease was not 304 
seen prior to recovery, 129/SvEv mice infected with ERA and PM exhibited overt 305 
neurological signs resembling those of mice lethally infected with DRV-4. On the basis of 306 
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these observations we can classify RV into three broad groups: 1/ attenuated viruses that are 307 
poorly neuroinvasive (HEP) and a CNS-targeted immune response and changes in BBB 308 
permeability are not required for clearance; 2/ attenuated neuroinvasive viruses that reach the 309 
CNS (ERA, PM, CVS-F3) but are cleared by immune effectors that cross the BBB; and 3/ 310 
neuroinvasive, lethal RV where there is no evidence of BBB permeability changes and 311 
negligible invasion of immune effectors into CNS tissues (DRV-4, SHBRV, Thai-DRV, 312 
CVS-N2c, CosRV, Skunk RV). 313 
Adoptive transfer of lymphocytes from 129/SvEv mice lethally infected with SHBRV 314 
can clear CVS-F3 from immunodeficient recipients while neither these cells nor similar cells 315 
from CVS-F3 - infected donors can clear SHBRV (Roy et al., 2007). We have interpreted 316 
these experiments as indicating that some aspect of the SHBRV infection restricts immune 317 
effectors from invading CNS tissues (Roy et al., 2007). PLSJL mice, which exhibit a stronger 318 
CNS inflammatory response, were found to have an elevated capacity to clear SHBRV (Roy 319 
and Hooper, 2007). To provide additional insight into whether or not some aspect of the host 320 
response is likely to be a contributing factor in RV infection we compared the outcome of 321 
infection with various RV strains in PLSJL and 129/SvEv mice. As previously shown for 322 
SHBRV (Roy and Hooper, 2007), DRV-4, CosRV and Skunk RV proved to be less 323 
pathogenic in PLSJL mice. In contrast, CVS-N2c and Thai-DRV are highly lethal for both 324 
PLSJL and 129/SvEv mice. The capacity of the virus to replicate and spread likely contributes 325 
to the outcome. At 8 days post infection high levels of CVS-N2c nucleoprotein mRNAs are 326 
present in the CNS of both infected 129/SvEv and PLSJL mice but only moderate levels of 327 
CosRV nucleoprotein mRNA in the lethally infected 129/SvEv CNS. These are somewhat 328 
reduced in the CNS of PLSJL mice that clear the infection, possibly as a consequence of the 329 
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initiation of immune-mediated virus clearance. Taken together these results indicate that both 330 
host and viral attributes contribute to the lethality of RV infection. In the absence of an 331 
effective CNS immune response RV infection is invariably lethal, as is the case for both CVS-332 
N2c and CosRV in 129/SvEv mice. On the other hand, PLSJL mice can survive infection with 333 
CosRV but not with the more rapidly replicating CVS-N2c. Conceivably, enhancing the 334 
extent of CNS inflammation may have utility in the treatment of RV such as CVS-N2c or 335 
Thai-DRV, as has been shown for SHBRV (Roy and Hooper, 2007), but we expect that there 336 
is level of infection at which an immune response would no longer be therapeutic.  337 
Human rabies is almost always lethal when neurological signs are apparent in the 338 
infected host. Since neurological signs are indicative of virus replication inside the CNS 339 
tissues, it has generally been considered that once RV has reached the brain it is impossible to 340 
clear the virus and the only hope that an individual has of surviving a RV infection is to 341 
prevent spread of the virus to the CNS. Thus people who have suffered a probable exposure to 342 
a RV are treated by passive administration of pre-formed (exogenous) RV-neutralizing 343 
antibodies and by boosting the development of their own (endogenous) RV-specific immunity 344 
by vaccination. These treatments, together known as PEP, are thought to act by preventing the 345 
spread of RV to the CNS, as they are largely ineffective when given to people who have 346 
already manifested neurological signs of rabies (CDC MMWR, 1999). However, this is not 347 
always the case. In 2004 a patient survived clinical rabies despite developing neurological 348 
signs evidently through the natural development of RV-specific immunity (Willoughby et al., 349 
2005). The appearance of white blood cells, virus specific antibodies and other serum proteins 350 
in the cerebrospinal fluid of this individual indicated that the BBB had been breached and that 351 
immune effectors likely had access to infected CNS tissues (Willoughby et al., 2005). Our 352 
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data comparing 129/SvEv and PLSJL mice suggest that host factors, in particular the capacity 353 
to deliver immune effectors across the BBB, play a large role in the ability to survive RV 354 
infection. This concept is supported by studies of rabies patients where significant serum RV-355 
specific antibody titers are often present (Kasempimolporn et al., 1991), but immune-356 
mediated changes in the CNS tissues are rare (Murphy, 1977).  357 
Human rabies associated with dog and other small carnivores is still a major public 358 
health problem in most parts of the world, dog rabies alone killing an estimated 50,000 – 359 
60,000 people annually (Dressen, 1997; Jackson, 2005). In the United States, around 30,000 360 
people receive anti-rabies treatment after being exposed to potentially rabid raccoons and 361 
skunks (CDC MMWR, 1999). While there is little objective proof, PEP is generally 362 
considered to be effective unless its administration is delayed, as is often the case for lethal 363 
infections with SHBRV where exposure to the virus may not be obvious (Messenger et al., 364 
2002). Proper administration of PEP has been known to fail to protect individuals bitten by 365 
rabid dogs on the face or other areas that are highly innervated, such as the fingertips (Wilde, 366 
2007). In such cases the virus may have reached peripheral nerves quickly after the exposure 367 
(Wilde, 2007). Our data would suggest that at some time after the virus has reached the CNS 368 
neither PEP nor natural RV-specific immunity can protect an individual because immune 369 
effectors are unable to enter the infected CNS tissues. However, we expect that there is a 370 
window of time where immune mechanisms can clear RV from the CNS before the infection 371 
shuts down the ability to deliver immune effectors into the CNS tissues. In the current study, 372 
we found that the RV strains ERA and PM can be cleared from the brain after development of 373 
prominent neurological signs of rabies. Our RT-PCR analysis of the CNS tissues confirmed 374 
extensive virus replication in the brain during infection with these RV strains. This suggests 375 
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that rabies is not invariably lethal if the virus can be cleared before neural damage, either 376 
caused by the virus or immunopathology, becomes too extensive. Thus, the predominant 377 
direct pathogenic attributes of a RV are likely related to its capacity to replicate and spread 378 
through CNS tissues (Dietzschold et al., 1985) as well as alter neuronal structure and function  379 
(Scott et al., 2008). We expect that these are in turn dependent upon the loss of the ability to 380 
support immune cell invasion across the BBB and limit virus spread. The caveat here is that 381 
the early development of CNS immunity is likely to be protective while the late development 382 
may be detrimental due to immunopathology consequential to more extensive virus spread. 383 
Notably, clear evidence of immunopathology was not seen with any of the RV studied here 384 
with the possible exception of ERA where an exaggerated immune response was evident in 385 
129/SvEv mice and one out of 15 animals died while the rest survived with neurological 386 
abnormalities. 387 
The concept that there is generally an inverse relationship between the pathogenicity 388 
of a RV and the capacity of the host to mediate an RV-specific CNS immune response is 389 
supported by the fact that there is little evidence of immune cell infiltration into the infected 390 
brain tissues of most individuals that succumb to rabies (Murphy, 1977). In a few human 391 
rabies cases CNS inflammation has been reported where immunopathology may have 392 
contributed to the death (Suja et al., 2004). While this has not been examined in humans, all 393 
of the RV strains studied in animal models induce strong innate, pro-inflammatory responses 394 
in the CNS as they reach these tissues (Marquette et al., 1996; Wang t al., 2006; Phares et al., 395 
2006; Fig. 3). Moreover, all RV are evidently highly immunogenic with infection inducing 396 
RV-specific antibodies in the sera of infected mice (Smith et al., 1982; Wiktor et al, 1977) as 397 
well as humans (Kasempimolporn et al., 1991). In addition, RV can evidently be cleared by 398 
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immune mechanisms without the immunopathology associated with CNS immune responses 399 
to many neurotropic viruses (Miller et al., 1990; Morimoto et al., 1996). Taken together these 400 
observations suggest that circumventing the inability of immune effectors to cross the BBB 401 
may have therapeutic benefits in people who have developed early signs of rabies. We have 402 
previously shown in mouse models that enhancing BBB permeability by the induction of 403 
autoimmune CNS inflammation can lead to the clearance of pathogenic RV strains from the 404 
brain via naturally developed anti-viral immunity. PLSJL mice, possibly due to an elevated 405 
capacity to mediate CNS inflammation, are less likely to die from rabies (Roy and Hooper, 406 
2007). These observations not only provide insight into how a rational treatment for rabies 407 
may be developed but also how conventional PEP may actually work. It has been well 408 
established that passive administration of rabies immunoglobulins (RIG) without active 409 
immunization fails to protect RV-infected experimental animals  (Hanlon et al., 2002). We 410 
speculate that active immunization accelerates the development of RV-specific adaptive 411 
immune cells capable of providing immune effectors access to infected neural tissues, a CD4 412 
T cell-dependent process (Phares et al., 2007), prior to the loss of the capacity to mediate this 413 
process at the BBB. Tailoring a next generation vaccine to target a mechanism that induces 414 
functional changes in BBB integrity in a manner that is not susceptible to inhibition may 415 
provide a means to survive rabies; if immunopathology can be limited and virus-mediated 416 
neuropathology is not extensive or can be reversed.  417 
 418 
 419 
 420 
 421 
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 529 
Table 1. Different strains of RV used for infection. 530 
RV Strains Species 
of origin 
Passage in the 
laboratory 
Amounts of 
virus in the 
inoculum 
(f.f.u)a 
References 
CVS-F3 (challenge virus 
standard, escape mutant) Dog Cell culture 1× 10
5
 
Dietzschold et al., 1983 
ERA (Evelyn Rokitnicki 
Abelseth) Dog Cell culture 1× 10
5
 
Abelseth, 1964 
PM (Pittman Moore) Dog Cell culture 1× 105 Rupprecht et al., 1992 
HEP (high egg passage –
flurry) Dog Cell culture 1× 10
5
 
Takayama-Ito et al., 2006 
SHBRV (silver haired bat-
associated rabies virus) Bat 
Neonatal mouse 
brain 1× 10
4
 
Dietzschold et al., 2000 
DRV-4 (dog rabies virus) Dog Neonatal mouse brain 1× 10
3
 
Dietzschold et al., 2000 
Thai-DRV (Thai- dog 
rabies virus) Dog 
Neonatal mouse 
brain 1× 10
5
 
Dietzschold et al., 2000 
CVS-N2c (challenge virus 
standard) Dog 
Neonatal mouse 
brainb 1× 10
5
 
Morimoto et al., 1999 
CosRV (Coyote rabies 
virus) Coyote 
Neonatal mouse 
brain 1× 10
4
 
Dietzschold et al., 2000 
Skunk RV Skunk Neonatal mouse brain 1 × 10
4
 
Rupprecht et al., 1987 
 531 
a 
 The number of foci developed in 20 hours of in-vitro cultured monolayer of baby hamster 532 
kidney (BHK) cells was counted as a measure of live virus particles in the inoculum. 533 
b 
 CVS-N2c was cloned in cell culture from parental CVS-24 strain, and then continued to 534 
passage in neonatal mouse brain. 535 
 536 
 537 
 538 
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Table 2. Survival of mice following infection with different RV strains a. 539 
129/SvEv PLSJL 
Virus 
Strains Mortality b Clinical 
signs 
% 
Survival Mortality 
Clinical 
signs 
% 
Survival 
CVS-F3 0/20 Piloerection, 
weight loss 100 0/10 100 
ERA 1/15 93 0/20 100 
PM 0/15 100 0/10 100 
DRV-4 10/10 
Piloerection, 
weight loss, 
hunched back, 
ataxia c 
0 0/10 
None 
 
100 
SHBRV 20/20 0 12/20 40 
Thai-
DRV 15/15 0 15/17 11 
CVS-N2c 20/20 
Piloerection, 
weight loss, 
sudden onsets 
of severe 
agitation, 
vellication, 
ataxia, apnea 0 18/20 
Dying: 
piloerection, 
weight loss, 
hunched back, 
apnea, 
vellication 
Surviving: no 
clinical sign 10 
CosRV 10/10 0 1/20 95 
Skunk 
RV 9/10 
Dying: weight 
loss, ataxia, 
piloerection 
Surviving: 
none 
10 1/10 
Dying: 
piloerection, 
weight loss, 
ataxia 
Surviving: 
none 
90 
HEP 0/15 None 100 0/10 None 100 
 540 
a 
  Two strains of mice were infected with different RV strains as described in the Materials 541 
and Methods and observed for clinical signs and mortality for a period of 30 days.  542 
b 
  Number of mice that died over total number of mice used to monitor survival following an 543 
infection.  544 
c 
  Clinical signs in 129/SvEv mice infected with ERA and PM begin to show 8-10 days post 545 
infection and stay for 8-10 more days. Mice infected with DRV-4 show similar signs but die 546 
within 3-4 days of the first appearance of clinical rabies. 547 
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FIGURE LEGENDS 548 
Figure 1. Detection of nucleoprotein message in the CNS of mice infected with different 549 
RV strains. RV nucleoprotein mRNA expression was detected in the CNS tissues (cerebral 550 
cortex and cerebellum) of mice infected with different RV strains 8 days previously, by RT-551 
PCR as described in Materials and Methods. Results of 4 randomly chosen mice (numbered 1, 552 
2, 3, 4) from each group of 10 mice are shown. 553 
 554 
Figure 2. Survival of mice following infection with different strains of RV. Groups of 10 555 
129/SvEv mice were infected with various RV strains listed in Table 1, via intra dermal 556 
injection as described in Materials and Methods. Mice were monitored for morbidity and 557 
mortality for 30 days. First 20 days observation is shown in the graph, there were no more 558 
deaths in any of the groups between 20 to 30 days post infection.  559 
 560 
Figure 3. Innate immune response in the cerebellar tissues following infection with 561 
different RV strains. Mice were infected with different RV strains as described in Materials 562 
and Methods. Eight days after infection, cerebellar tissues were collected and levels of 563 
mRNAs specific for TNF-α and IL-6 genes were measured using QRT-PCR as described in 564 
Materials and Methods. The levels of mRNA in each sample were normalized to the level of 565 
L13 gene expression in those samples and are expressed as the fold-increase over the 566 
expression levels detected in samples from uninfected control animals. Statistically significant 567 
differences in gene expression between infected and uninfected mice were calculated using 568 
Mann-Whitney test and are denoted by the symbol * (p < 0.01, n=10 in each group). 569 
 570 
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Figure 4. Serum anti-RV antibody titers of the mice infected with different RV strains. 571 
Sera were collected from the uninfected and infected mice (n=10 per group) described in the 572 
legend of Fig 3 and the amounts of RV-specific IgG molecules were measured using ELISA 573 
as described in Materials and Methods. Antibody titer in the Y-axis is the inverse of the 574 
dilution of a serum sample corresponding to the half of the maximum absorbance detected in 575 
that sample. Statistically significant (t-test comparison with non-immune sera) levels of RV-576 
specific antibody titers are seen in the sera of all infected mice.  577 
 578 
Figure 5. Accumulation of immune cells in the cerebellar tissues following infection with 579 
different RV strains. Levels of mRNAs specific for CD4, κ-light chain (κ-LC) and CD19 580 
genes were quantified using QRT-PCR in the total RNA isolated from the cerebellum of 581 
uninfected and infected mice described in the legend of Fig 3 and normalized to L13 gene 582 
expression in those samples as described in Materials and Methods. Levels of gene expression 583 
are represented as the fold-increase in mRNA copy numbers over normalized copies in 584 
samples from uninfected control animals as described in Materials and Methods. Statistically 585 
significant differences in gene expression between infected and uninfected mice were 586 
calculated using Mann-Whitney test and are denoted by the symbol ** p < 0.01 (n=10).  587 
 588 
Figure 6. BBB permeability changes in the cerebellum of the mice infected with different 589 
RV strains. BBB permeability was assessed by measuring the leakage of Na-fluorescein from 590 
the circulation into the cerebellum 8 days after RV infection and are expressed as the fold-591 
increase in Na-fluorescein uptake by the CNS tissues of RV infected mice over that of 592 
uninfected mice, as described in Materials and Methods. The dotted line represents the BBB 593 
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permeability in uninfected mice. Statistical significance of the differences in permeability 594 
between infected and uninfected mice was calculated using Mann-Whitney test and are 595 
denoted by the symbol ** p < 0.01, *** p<0.001 (n=10). 596 
 597 
Figure 7. Nucleoprotein message levels in the cerebellar tissues of 129/SvEv and PLSJL 598 
mice infected with CosRV and CVS-N2c RV strains. Eight days post infection QRT-PCR 599 
was used to quantify the levels of mRNAs specific for RV-nucleoprotein in total RNA 600 
isolated from the cerebellar tissues of mice infected with CosRV and CVS-N2c RV strains 601 
(n=5 per group). Levels normalized to L13 gene expression in the samples, as described in 602 
Materials and Methods, are presented. Significantly higher levels of nucleoprotein mRNA in 603 
CVS-N2c by comparison with CosRV infected mice are denoted by * (p<0.05, t-test). 604 
Significantly lower levels of nucleoprotein mRNA in PLSJL mice by comparison with 605 
129/SvEv mice are denoted by # (p<0.05, t-test). 606 
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